文献速递新发突发、热带与寄生虫病

辐射减毒全子孢子疟疾疫苗在加蓬儿童中的安全性与保护效力

Safety, tolerability, and protective efficacy of a radiation-attenuated, whole sporozoite malaria vaccine in children in Gabon: a randomised, double-blind, placebo-controlled, phase 2 trial.
PubMed 文献 · Lancet Infect Dis · 2025-09-16

这项在加蓬开展的随机双盲安慰剂对照2期试验纳入200名1-12岁健康儿童,按2:1分配接受9·0×10^5 PfSPZ疫苗或生理盐水,共三次直接静脉接种。疫苗耐受性良好,但接种后2-26周首次厚血涂片恶性疟原虫阳性时间分析显示年龄分层调整后疫苗效力仅9%(95%CI -75至53;p=0·78),未能预防感染。

要点

  • PfSPZ疫苗在1-12岁儿童中安全性和耐受性良好,未发现治疗相关死亡。
  • 疫苗组与安慰剂组系统性不良事件发生率相近(25% vs 23%)。
  • 疫苗未能预防恶性疟原虫感染,调整后效力9%(95%CI -75至53;p=0·78)。

核心结论

  • PfSPZ疫苗在加蓬1-12岁儿童中耐受性良好且安全,但未能预防恶性疟原虫感染。
  • 研究者提出免疫接种期间推定治疗或更强效PfSPZ疫苗能否建立保护效力正在研究中。

研究设计与样本

  • 随机、双盲、安慰剂对照2期试验,在加蓬Lambaréné的Centre de Recherches Médicales de Lambaréné开展。
  • 2018年6月21日至2019年4月30日评估345名儿童,入组200名,按年龄(1-2、3-6、7-12岁)分层,2:1区组随机分配。
  • 134名分配至9·0×10^5 PfSPZ疫苗组、66名分配至生理盐水安慰剂组,于第1、8、29天直接静脉接种,第三次接种前给予蒿甲醚-苯芴醇清除潜伏疟原虫。
  • 192名参与者接受三次接种并构成改良意向治疗人群;安全性在意向治疗人群中评估。

主要发现

  • 系统性不良事件:疫苗组134名中33名(25%,47起事件),安慰剂组66名中15名(23%,25起事件),主观发热为两组最常见事件。
  • 3起3级系统性不良事件(2例体温升高、1例主观发热)均发生于安慰剂组。
  • 22名参与者共报告32起严重不良事件:疫苗组134名中13名(10%),安慰剂组66名中9名(14%),均判定与干预无关。
  • 接种后2-26周厚血涂片恶性疟原虫阳性:疫苗组129名中25名(19%),安慰剂组63名中14名(23%)。
  • 年龄分层调整后疫苗效力(1-风险比)为9%(95%CI -75至53;p=0·78)。

关键数值与推荐

  • 共同主要终点为安全性和疫苗效力;安全性以接种后7天内征集性及28天内非征集性严重不良事件和严重不良事件评估。
  • 疫苗效力以接种后2-26周首次恶性疟原虫阳性厚血涂片时间衡量。
  • 疫苗剂量为9·0×10^5 PfSPZ,于第1、8、29天直接静脉接种。
  • 试验注册号ClinicalTrials.gov NCT03521973,已完成。

临床怎么用

  • 该结果不支持在加蓬1-12岁儿童中使用该剂量PfSPZ疫苗预防恶性疟原虫感染。
  • 该疫苗在本研究儿童人群中安全性良好,可作为后续疫苗研发与试验设计的安全性参考。
  • 接种期间推定治疗或更强效疫苗策略的效力尚待正在进行的研究验证。

局限性

  • 原文摘要未报告疫苗效力的年龄亚组分析结果。
  • 效力评估仅覆盖接种后2-26周,未提供更长随访数据。
  • 原文摘要未报告免疫原性指标及其与保护效力的关联。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Highly effective malaria vaccines are crucial to further reduce the burden of malaria. The radiation-attenuated Plasmodium falciparum sporozoite (PfSPZ) Vaccine protects adults; however, there are insufficient efficacy data in child populations. We aimed to assess the safety and efficacy of the PfSPZ Vaccine in children aged 1-12 years in Gabon. METHODS: This randomised, double-blind, placebo-controlled, phase 2 trial was conducted at the Centre de Recherches Médicales de Lambaréné, Lambaréné, Gabon. Healthy children were stratified by age (1-2, 3-6, and 7-12 years) and allocated 2:1 by block randomisation to receive 9·0 × 105 PfSPZ Vaccine or placebo (normal saline), administered by direct venous inoculation on days 1, 8, and 29. Artemether-lumefantrine was given before the third vaccination to clear latent parasitaemia. The co-primary endpoints were safety, evaluated in the intention-to-treat population by severe adverse events within 7 days (solicited) and 28 days (unsolicited) of vaccination and by serious adverse events; and vaccine efficacy, measured as time to first P falciparum-positive thick blood smear (TBS), 2-26 weeks after immunisation in those who received three vaccinations (ie, the modified intention-to-treat population). The trial was registered at ClinicalTrials.gov, NCT03521973, and is complete. FINDINGS: Between June 21, 2018, and April 30, 2019, 345 children were assessed for eligibility, of whom 200 were enrolled to the study: 134 were allocated to receive PfSPZ Vaccine and 66 to receive placebo. 192 participants received three vaccinations and comprised the modified intention-to-treat population. Systemic adverse events were reported by 33 (25%) of 134 participants in the vaccine group (47 events) and 15 (23%) of 66 participants in the placebo group (25 events); subjective fever was the most reported event in both groups. Three grade 3 systemic adverse events were reported (two cases of elevated body temperature and one case of subjective fever), all in the placebo group. 32 serious adverse events were reported across 22 study participants, 13 (10%) of 134 in the vaccine group and nine (14%) of 66 in the placebo group, all of which were considered unrelated to the intervention. There were no treatment-related deaths. 25 (19%) of 129 vaccine recipients and 14 (23%) of 63 placebo recipients became TBS-positive for P falciparum at 2-26 weeks after vaccination. The age-stratum-adjusted vaccine efficacy (1 - hazard ratio) was 9% (95% CI -75 to 53; p=0·78). INTERPRETATION: PfSPZ Vaccine is well tolerated and safe, but it did not prevent P falciparum infection in children in Gabon. Whether presumptive treatment during immunisation or more potent PfSPZ vaccines can establish vaccine efficacy is currently under investigation. FUNDING: German Center for Infection Research, European and Developing Countries Clinical Trials Partnership, National Institute of Allergy and Infectious Diseases, National Institutes of Health, and Sanaria.

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. Agnandji ST, Bok J, Alabi A, et al. Safety, tolerability, and protective efficacy of a radiation-attenuated, whole sporozoite malaria vaccine in children in Gabon: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis. 2025. PMID: 40972633. doi:10.1016/S1473-3099(25)00434-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。